同时,基于多个临床前模型中的有希望结果和有利的I期临床安全性,我们将探索LX9211在其他神经源性疼痛领域的机会。” 原文出处:Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain 原标题:糖尿病...
Confirmation of these positive results are planned in future Phase 3 trials.RODICA BUSUIANAND PATELCHRISTINE N. SANGCRAIG B. GRANOWITZPHILLIP L. BANKSPHILLIP PIERCEFRANKLIN W. SUNSUMA GOPINATHANDiabetes
Lexicon Pharmaceuticals, Inc. today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabet...